Akero Therapeutics Inc (AKRO)

NASDAQ
Currency in USD
25.14
+1.13(+4.71%)
Closed
After Hours
25.01-0.13(-0.52%)
AKRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
24.0525.63
52 wk Range
15.3237.00
Key Statistics
Edit
Prev. Close
24.01
Open
24.33
Day's Range
24.05-25.63
52 wk Range
15.32-37
Volume
1.23M
Average Vol. (3m)
676.69K
1-Year Change
16.55%
Book Value / Share
10.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AKRO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
48.27
Upside
+92.02%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period
Show more

Akero Therapeutics Inc Company Profile

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Compare AKRO to Peers and Sector

Metrics to compare
AKRO
Peers
Sector
Relationship
P/E Ratio
−7.4x−2.6x−0.6x
PEG Ratio
0.13−0.040.00
Price / Book
2.4x2.0x2.6x
Price / LTM Sales
-16.1x3.1x
Upside (Analyst Target)
94.9%367.5%53.0%
Fair Value Upside
Unlock34.7%8.0%Unlock

Analyst Ratings

10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 48.27

(+92.02% Upside)

Earnings

Latest Release
Nov 08, 2024
EPS / Forecast
-1.05 / -0.8787
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

9.8300
QUBT
-9.65%
28.24
HMC
+0.97%
385.29
ELV
+0.01%
242.05
COR
+0.48%
61.16
APTV
-0.28%

FAQ

What Is the Akero Therapeutics (AKRO) Stock Price Today?

The Akero Therapeutics stock price today is 25.14

What Stock Exchange Does Akero Therapeutics Trade On?

Akero Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Akero Therapeutics?

The stock symbol for Akero Therapeutics is "AKRO."

What Is the Akero Therapeutics Market Cap?

As of today, Akero Therapeutics market cap is 1.75B.

What is Akero Therapeutics Earnings Per Share?

The Akero Therapeutics EPS is -3.74.

What Is the Next Akero Therapeutics Earnings Date?

Akero Therapeutics will release its next earnings report on Mar 13, 2025.

From a Technical Analysis Perspective, Is AKRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.